We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Targeting MicroRNA Blocks Drug Tolerance in Some Cancers

By LabMedica International staff writers
Posted on 15 Apr 2019
Print article
Image: A diagram of the epidermal growth factor receptor (EGFR) (rainbow colored, N-terminus = blue, C-terminus = red) complexed its ligand epidermal growth factor (magenta) (Photo courtesy of Wikimedia Commons).
Image: A diagram of the epidermal growth factor receptor (EGFR) (rainbow colored, N-terminus = blue, C-terminus = red) complexed its ligand epidermal growth factor (magenta) (Photo courtesy of Wikimedia Commons).
Cancer researchers have suggested that by exploiting the link between a specific microRNA and the tricarboxylic acid energy-producing cycle it may be possible to prevent or reverse the development of drug tolerance or resistance by non-small-cell lung carcinomas.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

Non-small cell lung cancers, which comprise about 85% of lung cancer diagnoses, tend to be less aggressive but harder to treat than small cell lung cancers. About 10% of non-small-cell lung carcinomas carry an epidermal growth factor receptor (EGFR) mutation. Drug tolerance developed by cancer cells is an acute defense response preceding a fully drug-resistant state and tumor relapse; however, there are few therapeutic agents targeting drug tolerance in the clinic.

As part of their effort to identify drugs able to modify drug tolerance, investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) found that the microRNA miR-147b initiated a reversible state of tolerance to the epidermal growth factor receptor (EGFR) inhibitor osimertinib in non-small-cell lung cancer. Osimertinib is a medication used to treat non-small-cell lung carcinomas with the specific EGFR mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

The investigators reported in the April 8, 2019, online edition of the journal Nature Metabolism that using miRNA-seq analysis, they determined that miR-147b was the most upregulated microRNA in osimertinib-tolerant and EGFR-mutated lung cancer cells. Whole-transcriptome analysis of single-cell-derived clones revealed a link between osimertinib tolerance and pseudohypoxia responses irrespective of oxygen levels.

Further metabolomics and genetic studies demonstrated that osimertinib tolerance was driven by miR-147b-mediated repression of VHL (von Hippel-Lindau tumor suppressor) and succinate dehydrogenase, which are linked to the tricarboxylic acid energy-producing cycle and pseudohypoxia pathways. Finally, pretreatment with a miR-147b inhibitor delayed osimertinib-associated drug tolerance in patient-derived three-dimensional structures.

"These results were a surprise and represent a total novel finding in the area," said senior author Dr. Frank J. Slack, professor of medical research at Beth Israel Deaconess Medical Center. "In this study, we discovered that a microRNA known as miR-147b is a critical mediator of resistance among a subpopulation of tumor cells that adopt a tolerance strategy to defend against EGFR-based anticancer treatments. We are currently testing the idea of targeting this new pathway as a therapy in clinically relevant mouse models of EGFR-mutant lung cancer."

Related Links:
Beth Israel Deaconess Medical Center

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Gold Member
Troponin T QC
Troponin T Quality Control
New
Silver Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hematology Analyzer
XS-500i

Print article

Channels

Microbiology

view channel
Image

POC PCR Test Rapidly Detects Bacterial Meningitis Directly at Point of Sample Collection

Meningitis is an inflammation of the membranes surrounding the brain and spinal cord. Pathogens typically enter the body through the respiratory tract and spread via the bloodstream. The infection can... Read more

Pathology

view channel
Image: The unique AI tool predicts cancer prognoses and responses to treatment (Photo courtesy of Shutterstock)

AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.